Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sequential reduced-dose chemotherapy and blinatumomab in older adults with newly diagnosed CD19-positive Ph/BCR-ABL-negative B-precursor ALL
2017-002853-13Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Oct 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Primary endpoint: Complete hematologic remission rate after induction. Started Oct 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2017-002853-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002853-13.